F8-IL10: A New Potential Antirheumatic Drug Evaluated by a PET-Guided Translational Approach
Open Access
- 14 December 2018
- journal article
- research article
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 16 (1) , 273-281
Abstract
Antibody fragment F8- mediated Interleukin 10 (IL10) delivery is a novel treatment for rheumatoid arthritis (RA). F8 binds to the extra-domain-A of fibronectin (ED-A). In this study, in-vivo biodistribution and arthritis targeting of radiolabeled F8-IL10 were investigated in RA patients, followed by further animal studies. Therefore, three RA patients (DAS28 >3.2) received 0.4 mg, 30-74 megabecquerel [124I]I-F8-IL10 for PET-CT and blood sampling. In visually identified PET-positive joints target-to-background were calculated. Healthy mice, rats, and arthritic rats were injected with iodinated F8-IL10 or KSF-IL10 control antibody. Various organs were excised, weighed and counted for radioactivity. Tissue sections were stained for fibronectin ED-A. In RA patients, [124I]I-F8-IL10 was cleared rapidly from the circulation with less than 1% present in blood after 5 minutes. PET-CT showed targeting in 38 joints (11-15 per patient) and high uptake in liver and spleen. Mean target-to-background ratios of PET-positive joints were 2.5±1.2, and 1.5 times higher for clinically active than clinically silent joints. Biodistribution of radioiodinated F8-IL10 in healthy mice showed no effect of radioiodination method. [124I]I-F8-IL10 joint uptake was also demonstrated in arthritic rats, ~14 fold higher than control antibody [124I]I-KSF-IL10 (p< 0.001). Interestingly, liver and spleen uptake was twice as high in arthritic than in healthy rats and was related to increased (~7x) fibronectin ED-A expression in these tissues. In conclusion, [124I]I-F8-IL10 uptake was observed in arthritic joints in RA patients holding promise for visualization of inflamed joints by PET-CT imaging and therapeutic targeting. Patient observations and subsequently arthritic animal studies pointed to awareness of increased [124I]I-F8-IL10 uptake in liver and spleen associated with moderate systemic inflammation. This translational study demonstrated the value of in vivo biodistribution and PET-CT guided imaging in development of new and potential anti-rheumatic drugs’.Keywords
Funding Information
- FP7 Health
This publication has 36 references indexed in Scilit:
- Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritisNature Reviews Rheumatology, 2013
- Anti-citrullinated fibronectin antibodies in rheumatoid arthritis are associated with human leukocyte antigen-DRB1shared epitope allelesArthritis Research & Therapy, 2012
- Impact of the Definition of Peak Standardized Uptake Value on Quantification of Treatment ResponseJournal of Nuclear Medicine, 2012
- Combination of temozolomide with immunocytokine F16–IL2 for the treatment of glioblastomaBritish Journal of Cancer, 2010
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugsAnnals of the Rheumatic Diseases, 2010
- Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritisArthritis Research & Therapy, 2009
- 124I-L19-SIP for immuno-PET imaging of tumour vasculature and guidance of 131I-L19-SIP radioimmunotherapyEuropean Journal of Nuclear Medicine and Molecular Imaging, 2009
- The Extra-domain A of Fibronectin Is a Vascular Marker of Solid Tumors and MetastasesCancer Research, 2007
- Modification of low-density lipoprotein by different radioiodination methodsNuclear Medicine and Biology, 2004
- The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritisArthritis & Rheumatism, 1988